Latest Biotechnology, Pharmaceutical and Healthcare News from Seeking Alpha

00:01 EDT 23rd September 2017 | BioPortfolio

Here are the most relevant search results for "Seeking Alpha" found in our extensive news archives from over 250 global news sources.

More Information about Seeking Alpha on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Seeking Alpha for you to read. Along with our medical data and news we also list Seeking Alpha Clinical Trials, which are updated daily. BioPortfolio also has a large database of Seeking Alpha Companies for you to search.

Showing News Articles 1–25 of 20,000+ from Seeking Alpha

Friday 22nd September 2017

Expect A Slow Bleed With Portola Pharma

MannKind: Afrezza Scripts Rebound To Highest Level Yet Under MannKind Control

Why We Bought Gilead This Week

Allergan Is A Bargain

Biotech Forum Daily Digest: Patient Deaths Hit Intercept Pharma

Teladoc: Buying The Healthcare Future At A Discount

Seres Therapeutics Is Hiding A Volatile Catalyst

Your Daily Pharma Scoop: VanEck Vectors Biotech ETF, Esperion's Growth Potential, Pfizer's EU Approval

Savara: An Excellent Short Opportunity With 38% Downside Possible

Redhill BioPharma: Highly De-Risked And Undervalued With A Deep Pipeline

Aradigm: Hidden Binary Event Or Russian Roulette (With The FDA Spinning The Chamber)?

3 Things In Biotech You Should Learn Today: September 22, 2017

Anthem Agrees To Acquire HealthSun For Integrated Network

Johnson & Johnson Acquires Sightbox For Contact Lens Subscriptions

Thursday 21st September 2017

Esperion Therapeutics Remains Undervalued

Gene Editing Could Modify And Cure Disease: CRISPR Vs. TALENs

Continued Trouble Ahead For Ardelyx

Argos Therapeutics (ARGS) Interim Analysis Of The Phase 3 Adapt Trial Evaluating Rocapuldencel - T (AGS-003) - Slideshow

Alnylam Pharmaceuticals (ALNY) Updates On Apollo Phase 3 Study of Patisiran (Topline Results) - Slideshow

TSO3 Inc.: Taking The Fight To The Superbugs

Don't Get Suckered Into Cumberland Pharmaceuticals

CRISPR Field - Patent Fight Extended: Focus On Science, Time Frames, Risks

Nabriva Looks To Another Phase 3 To Seal The Deal

ROTY Volume 1 Edition 32: Learning From Mistakes And Additional Trades

Mirati Brings Hope With Its Stellar Performance

Quick Search

News Quicklinks